Labcorp Holdings

LH · NYSE

$323.13+$4.30 (+1.35%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $318.83

LH analyst rating

BuyConsensus of 10 analysts over the last 12 months. 70% rate it a buy.

Strong buy0
Buy7
Hold3
Underperform0
Sell0

12-month price target · 20 analysts

Average $350.79 (+8.6% upside)

Low: $297.61
Now: $323.13
High: $404.25

Upgrades and downgrades

The latest rating actions, newest first

LH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Sep 21, 2026	Maintains	Buy	$350.00 → $365.00	67%
UBS	Sep 11, 2026	Maintains	Buy	$361.00 → $380.00	70%
Barclays	Sep 11, 2026	Maintains	Equal-Weight	$320.00 → $330.00	54%
Piper Sandler	Aug 4, 2026	Maintains	Neutral	$300.00 → $309.00	58%
JP Morgan	Aug 3, 2026	Maintains	Overweight	$330.00 → $360.00	54%
Morgan Stanley	Jul 31, 2026	Maintains	Overweight	$308.00 → $338.00	67%
Truist Securities	Jul 31, 2026	Maintains	Buy	$320.00 → $350.00	67%
Barclays	Jul 31, 2026	Maintains	Equal-Weight	$290.00 → $320.00	69%
B of A Securities	Jul 13, 2026	Maintains	Buy	$300.00 → $320.00	53%
Baird	Jul 13, 2026	Maintains	Outperform	$335.00 → $338.00	64%

The case for and against

Updated Jan 12, 2026

Bull case

Labcorp Holdings demonstrates strong financial performance, evidenced by a 7.5% revenue increase in its Central Lab segment, primarily driven by significant trial wins and the introduction of advanced digital pathology and AI solutions. Additionally, the Diagnostic segment recorded solid revenue growth of 8.9% year-over-year, supported by both organic growth and acquisitions contributing equally to this increase. Furthermore, the company showcases robust operational metrics with a backlog of $8.71 billion, reflecting a 10% year-over-year improvement and a net book-to-bill ratio of 1.11x, indicating positive momentum and demand for its services.

Bear case

The financial outlook for Labcorp Holdings is negatively influenced by several key risks, including adverse shifts in reimbursement policies under the Protecting Access to Medicare Act (PAMA) and challenges related to the integration of acquisitions. Additionally, increased competition and economic uncertainty further exacerbate the company's financial stability, potentially impacting revenue growth. Although total requisitions showed a modest increase of 4.9%, this figure fell short of the anticipated growth of 5.2%, highlighting potential weaknesses in organic volume performance and overall market positioning.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.